Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.

Ayesha RehmanShahab SaidullahMuhammad AsadUmer R GondalAmna AshrafMuhammad F KhanWaheed AkhtarAmin MehmoodiJahanzeb Malik

Published in: Clinical cardiology (2024)

Semaglutide demonstrated significant clinical benefits in HFpEF patients with obesity, as evidenced by improved symptoms, physical function, and weight reduction.

Keyphrases

weight loss
weight gain
insulin resistance
metabolic syndrome
high fat diet induced
type diabetes
body mass index
physical activity
adipose tissue
depressive symptoms